Chimerix Inc. (CMRX) and Zafgen Inc. (NASDAQ:ZFGN) Comparison side by side

Chimerix Inc. (NASDAQ:CMRX) and Zafgen Inc. (NASDAQ:ZFGN) compete against each other in the Biotechnology sector. We will contrast them and contrast their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chimerix Inc. 4.20M 27.20 73.76M -1.55 0.00
Zafgen Inc. N/A 0.00 59.88M -2.04 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Chimerix Inc. and Zafgen Inc.


Table 2 has Chimerix Inc. and Zafgen Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Chimerix Inc. -1,756.19% -36.5% -34.7%
Zafgen Inc. 0.00% -80.1% -58.4%

Volatility & Risk

A 1.2 beta indicates that Chimerix Inc. is 20.00% more volatile compared to Standard & Poor’s 500. Competitively, Zafgen Inc. is 135.00% less volatile than Standard & Poor’s 500, because of the -0.35 beta.


Chimerix Inc.’s Current Ratio and Quick Ratio are 19.9 and 19.9 respectively. The Current Ratio and Quick Ratio of its competitor Zafgen Inc. are 11.8 and 11.8 respectively. Chimerix Inc. therefore has a better chance of paying off short and long-term obligations compared to Zafgen Inc.

Analyst Ratings

In next table is given Chimerix Inc. and Zafgen Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Chimerix Inc. 0 0 0 0.00
Zafgen Inc. 0 0 1 3.00

Insider and Institutional Ownership

Institutional investors owned 82.3% of Chimerix Inc. shares and 91.5% of Zafgen Inc. shares. About 0.6% of Chimerix Inc.’s share are owned by insiders. Comparatively, insiders own roughly 0.3% of Zafgen Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Chimerix Inc. 2.74% -5.85% -11.52% -24.89% -25.55% -27%
Zafgen Inc. 1.79% -49.46% -46.73% -21.8% 33.25% 11.04%

For the past year Chimerix Inc. had bearish trend while Zafgen Inc. had bullish trend.


Chimerix Inc. beats Zafgen Inc. on 6 of the 10 factors.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases. Zafgen, Inc. was founded in 2005 and is based in Boston, Massachusetts.